Articles tagged "Hepatocellular carcinoma"

2017 American Transplant Congress
A New Strategy for Loco-Regional Therapy of Hepatocellular Carcinoma: Stereotactic Body Radiotherapy as a Bridge to Liver Transplantation.
T. Uemura,¹ A. Kirichenko,² M. Bunker,³ M. Vincent,¹ L. Machado,¹ A. Singhal,¹ N. Thai.¹
¹Transplant Surgery, Allegheny General Hospital, Pittsburgh; ²Radiation Oncology, Allegheny General Hospital, Pittsburgh; ³Pathology, Allegheny General Hospital, Pittsburgh
Background: Transarterial chemoembolization (TACE) or radiofrequency ablation are often used as local Hepatocellular Carcinoma (HCC) treatment while waiting for a liver transplant (LTx). However, it…
2017 American Transplant Congress
Exception Scores for Patients on the Liver Waiting List.
T. Weaver,¹ D. Schladt,¹ M. Skeans,¹ J. Pyke,¹ J. Zeglin,¹ S. Leppke,¹ A. Israni,^1,2 B. Kasiske,^1,2 W. Kim,³ J. Lake.⁴
¹Scientific Registry of Transplant Recipients, Minneapolis, MN; ²Hennepin County Medical Center, Minneapolis, MN; ³Stanford University, Stanford, CA; ⁴University of Minnesota, Minneapolis, MN
Liver waitlist candidates are prioritized for allocation using model for end-stage liver disease (MELD) scores, and some patients receive higher MELD scores through exception. The…
2017 American Transplant Congress
Recurrent HCC After Radiofrequency Ablation or Liver Resection Can Be Effectively Treated with Salvage Transplantation.
H. Muaddi,¹ D. Al-Adra,¹ J. Shaw,¹ D. Grant,¹ P. Greig,¹ I. McGilvray,¹ M. Cattral,¹ A. Wei,¹ C.-A. Moulton,¹ J. Kachura,² R. Beecroft,² M. Selzner,¹ A. Ghanekar,¹ S. Gallinger,¹ S. Cleary,¹ G. Sapisochin.¹
¹General Surgery, University of Toronto, Toronto, ON, Canada; ²Medical Imaging, University of Toronto, Toronto, ON, Canada
Background:Liver resection (LR) and radiofrequency ablation (RFA) represent curative therapies for early stages of hepatocellular carcinoma (HCC). If tumour recurrence occurs, salvage liver transplant (SLT)…
2017 American Transplant Congress
HCV Eradication with DAA Therapy Should Be Attempted Prior to Liver Transplantation and Does Not Impact HCC Recurrence.
J. Emamaullee, M. Bral, G. Meeberg, A. Montano-Loza, V. Bain, D. Bigam, N. Kneteman, A. Shapiro.
University of Alberta, Edmonton, AB, Canada
Background: Recent advances in the direct-acting antiviral (DAA) treatment of HCV have lead to high rates of HCV eradication, even in patients with decompensated cirrhosis.…
2017 American Transplant Congress
Current Treatments for Small Hepatocellular Carcinoma: A Network Meta-Analysis of Randomized Controlled Trials.
Z. Guo, Z. Zheng, X. He, G. Chen.
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Purpose: Numerous randomized controlled trials (RCTs) concerning treatments for small hepatocellular carcinoma (HCC) have been reported. Herein, we conducted a network meta-analysis integrating current evidence…
2017 American Transplant Congress
Outcome After Living Donor Liver Transplantation for Hepatocellular Carcinoma in Elderly Patients > 65 Years: Assessing the Long Term Survival.
A. Thorat, S.-C. Hsu, L.-B. Jeng, H.-R. Yang, P.-C. Li, C.-C. Yeh, T.-H. Chen, K.-S. Poon.
Organ Transplantation, China Medical University Hospital, Taichung, Taiwan
Background:In Asia, the hepatocellular carcinoma (HCC) is most common cancer. Despite of the surveillance most tumors are diagnosed at late stages and thus HCC continues…
2017 American Transplant Congress
Multicenter Validation of a Clinicopathologic Risk Score to Predict Hepatocellular Carcinoma Recurrence Following Liver Transplantation: Analysis of 4984 Patients from the US Multicenter HCC Transplant Consortium.
V. Agopian, On Behalf of the US Multicenter HCC Transplant Consortium.
UCLA, LA
Objective: Recurrence of hepatocellular carcinoma (HCC) following liver transplantation (LT) negatively impacts survival. Existing risk prediction models either lack external validation or limit their scope…
2017 American Transplant Congress
Pre-TACE Immune Status Correlates with Treatment Response and Tumor Biology in HCC as a Bridge to Transplant.
T. Sandow,¹ H. Bohorquez,² D. Kirsch,¹ A. Albar,¹ P. Thevenot,³ K. Nunez,³ D. DeVun,¹ J. Gimenez,¹ G. Galliano,⁴ A. Cohen,² G. Loss,² D. Kay,¹ P. Gulotta.¹
¹Radiology, Ochsner Clinic Foundation, New Orleans, LA; ²Transplant Surgery, Ochsner Clinic Foundation, New Orleans, LA; ³Institute of Translational Research, Ochsner Clinic Foundation, New Orleans, LA; ⁴Pathology, Ochsner Clinic Foundation, New Orleans, LA
Purpose:Immune factors are pivotal against disease progression after transplant in hepatocellular carcinoma (HCC). With chemoembolization (TACE) as a bridge to liver transplant, this study compares…
2017 American Transplant Congress
A Pretransplant Model Incorporating Serum Biomarkers Is Superior to the Milan Criteria in Stratifying Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation: Analysis of 4407 Patients from the US Multicenter HCC Transplant Consortium.
V. Agopian, On Behalf of the US Multicenter HCC Transplant Consortium.
UCLA, LA
Objective: While adoption of the Milan Criteria (MC) has improved outcomes following liver transplantation (LT) for hepatocellular carcinoma (HCC), recurrence remains a significant challenge. We…
2017 American Transplant Congress
Re-Evaluation of Imaging Studies in Patients with Hepatocellular Carcinoma at a Transplant Center Impacts Patient Care.
A. Kardashian, B. Madani, C. Frenette.
Organ Transplant, Scripps Clinic, La Jolla, CA
Introduction: The United Network for Organ Sharing (UNOS) requires confirmation of HCC based on imaging to be made at a transplant center. This places a…